Tumour-specific cytotoxicity and MDR-reversal activity of dihydropyridines

In Vivo. 2006 Sep-Oct;20(5):637-43.

Abstract

The ability of 41 1,4-diphenyl-1,4-dihydropyridine derivatives to inhibit the transport activity of P-glycoprotein were studied by flow cytometry in a multidrug-resistant human colon cancer cell line (COLO320) and in human mdr1 gene-transfected mouse lymphoma cells (L 5178 Y). The cytotoxicities of these compounds were also examined against human normal and cancer cell lines. The majority of the tested compounds proved to be effective inhibitors of rhodamine 123 outward transport, but their cytotoxicities were not negligible. Some dihydropyridine derivatives displayed cytotoxic activity against four human oral tumour cell lines and against three normal human oral cell lines. There was no clear-cut relationship between the multidrug-resistance activity or cytotoxicity and the chemical structures of the compounds. New ring substituents could prevent the oxidation of the ring of the aromatic compound.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • ATP Binding Cassette Transporter, Subfamily B, Member 1 / antagonists & inhibitors*
  • Animals
  • Antineoplastic Agents / toxicity*
  • Cell Line
  • Cell Line, Tumor
  • Dihydropyridines / pharmacokinetics
  • Dihydropyridines / toxicity*
  • Drug Resistance, Multiple*
  • Drug Resistance, Neoplasm*
  • Humans
  • Mice
  • Molecular Structure
  • Transfection

Substances

  • ATP Binding Cassette Transporter, Subfamily B, Member 1
  • Antineoplastic Agents
  • Dihydropyridines